GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 157-168 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.

Kitsios K; Trakatelli CM

Jan 1, 2026

2026PubMedDirectly related

Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gamal I; Elkasaby MH; Ewidat O; Riyad N; Sadin Z; Singh Gill A; Nassar M; Frishman WH; Aronow WS

Jan 1, 2026Cardiology in review

2026PubMedDirectly related

Oral Incretin-Based Therapies for Weight Management.

Cheng HE; Bonafede M; Shukla AP

Jan 1, 2026Current atherosclerosis reports

2026PubMedDirectly related

Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis.

Shirmohammadi E; Ghasemloo N; Ebrahimi N; Mohammadzadeh N; Ehtemami A; Babaei M; Fardoost S

Jan 1, 2026Endocrinology, diabetes & metabolism

2026PubMedDirectly related

Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.

Tavaglione F; Loomba R

Jan 1, 2026Cell reports. Medicine

2026PubMedDirectly related

Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.

Lee CM; Kim JY; Shim JH; Cho GW

Jan 1, 2026Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

2026PubMedDirectly related

Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.

Choi JG; Gong EJ; Bang CS; Lee JJ

Jan 1, 2026Gut and liver

2026PubMedDirectly related

Patient-Reported Continuity of GLP-1 Receptor Agonist Therapy.

Chen Y; Piantek G; Zhang X; Feng Y; Yan C; Samuels JM; Rosenbloom ST; Yu D; Novak LL; Srivastava G

Jan 1, 2026Obesity science & practice

2026PubMedDirectly related

Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report.

Fougerousse AC

Jan 1, 2026Clinical, cosmetic and investigational dermatology

2026PubMedDirectly related

Pharmacological management of obesity: Current landscape and emerging therapies.

Atal S; Agrawal C; Gupta R; Sadasivam B

Jan 1, 2026Indian journal of pharmacology

2026PubMedDirectly related

Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study.

Tournayre S; Bonnet JB; Anitcheou J; Faivre M; Boegner C; Jalek A; Jullien D; Le Rouzic C; Attalin V; Myzia J; Kemba Y; Sultan A; Avignon A

Jan 1, 2026Journal of medical Internet research

2026PubMedDirectly related

Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV(1).

Mirfakhraee S; Abreu M; Singh A; Ratti GA; Finklea JD; Jain R; Abramowitz J

Jan 1, 2026Respiratory medicine